Breast cancer is one of the most common malignant tumors in women, ranking the first in the list of fatal malignant tumors among urban women. For example in Beijing and Shanghai, breast cancer has become the highest incidence of malignant tumors in women and is still increasing at an annual rate of 2-3%, a serious threat to the lives of women.

At present, "precision therapy" concept brings a broader perspective of clinical and scientific research. Genetic detection of tumors could satisfy personalized requirements of early-stage interference and treatment, commonly expected by both researchers and clinicians. SITI and Fudan University Shanghai Cancer Center collaborated in the development of breast cancer gene detection product based on second generation sequencing (NGS) technology, which is clinically significant and valuable in propelling of breast cancer early warning and early diagnosis, personalized precision, and improvement of cure and survival rates.